Bluejay Diagnostics, Inc. — Form 8-K
Filed October 6, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Bluejay announced clinical baseline data from its SYMON-II pivotal study of IL-6 as a prognostic biomarker for sepsis mortality. The study enrolled 777 evaluable patients (637 survivors, 140 non-survivors; 18% 28-day mortality rate) with broad illness severity and geographic distribution. The company plans to use SYMON-II results to support a 510(k) FDA submission for its Symphony IL-6 Test, which remains unapproved and commercially unavailable in the U.S.
Why this rating
Major clinical milestone (pivotal study baseline) for $2.6M market-cap company; validates patient population for FDA pathway; material to regulatory trajectory but not yet proven efficacy.
Tradability signal
NO TRADE
No trade: positive news with only +0.8% moved so far — good news prices in within seconds and long-side continuation has shown no measured edge (this cell: +0.01% over 4 hrs, n=189). (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
before filing · preread $0.78 ▼ 0.12% | at our read · unknown $0.78 | +10 min · unknown $0.77 ▼ 0.83% | +30 min pending | +1 hr pending | +4 hrs pending |
The stock had already moved +0.12% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from October 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.